Kolorektalkarzinom

Titel
Studie
Jahr

An observational study to evaluate the effectiveness of OnLife® in improving chemotherapy-induced peripheral neuropathy in patients with colon or breast cancer after end of adjuvant therapy: Design of the STEFANO trial.

Zaiss, M., Uhlig, J., Zahn, M.-O., Decker, T., Lehmann, H., Harde, J., Hogrefe, C., Vannier, C., Marschner, N., 2018.

Oncol Res Treat 41 (suppl 4)(P945).

Indikation: KolorektalkarzinomMammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

STEFANO
2018

Systemic palliativ treatment and outcome in later lines in patients with metastatic colorectal cancer – Real-life data from the clinical Tumour Registry Colorectal Cancer (TKK).

Schnell, R., Uhlig, J., Eggers, E., Jänicke, M., Fleitz, A., Wetzel, N., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P587).

Indikation: Kolorektalkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TKK
2017

Application study of the EQ-5D-5L in Oncology: Linking self-reported quality of life of patients with metastatic colorectal cancer to clinical data from a German tumor registry.

Borchert, K., Jacob, C., Wetzel, N., Jänicke, M., Eggers, E., Sauer, A., Marschner, N., Meise, D., Altevers, J., Mittendorf, T., Braun, S., Greiner, W., 2017.

ISPOR 20th Annual European Congress. Cancer: Clinical Outcomes Studies.

Indikation: Kolorektalkarzinom; Veranstaltung: ISPOR; Journal: -

TKK
2017

Bevacizumab (Bev)-based combination therapy across treatment lines in patients (pts) with metastatic colorectal cancer (mCRC)-interim analysis results from a German non-interventional study (KORALLE).

Eggers, E., Uhlig, J., Reichert, D., Wein, A., Schulz, H., Behringer, A., Arnold, D., 2017.

Oncol Res Treat, 40(suppl 3)(P577), 162-163.

Indikation: Kolorektalkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

KORALLE
2017

Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.

Schimanski, C.C., Staib, F., Göhler, T., Hebart, H., Heike, M., Neise, M., Rudi, J., Geer, T., Dingeldein, G., Lang, C., Ehscheidt, P., Flohr, T., Josten, K.M., Karthaus, M., Schmittel, A., Wierecky, J., Boller, E., Indorf, M., Wörns, M.-A., Galle, P.R., Moehler, M., 2017.

J. Cancer Res. Clin. Oncol. 143(6), 1023–1034. doi:10.1007/s00432-017-2344-3

Indikation: Kolorektalkarzinom; Veranstaltung: -; Journal: Journal of Cancer Research and Clinical Oncology

DERMATUX
2017

Dermatux: Phase IV trial of C-FOLFIRI in 1st-line metastatic colorectal cancer receiving a pre-defined skin care.

Schimanski, C.C., Staib, F., Goehler, T., Hebart, H.F., Neise, M., Rudi, J., Geer, T., Ehscheidt, P., Flohr, T., Schmittel, A.H., Galle, P.R., Moehler, M.H., 2016.

J Clin Oncol 34 (suppl; abstr e15048). doi:10.1200/JCO.2016.34.15_suppl.e15048

Indikation: Kolorektalkarzinom; Veranstaltung: ASCO; Journal: Journal of Clinical Oncology

DERMATUX
2016

Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial.

Quidde, J., Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C., Killing, B., Depenbusch, R., Steffens, C.-C., Lange, T., Dietrich, G., Stoehlmacher, J., Reinacher, A., Tannapfel, A., Trarbach, T., Marschner, N., Schmoll, H.-J., Hinke, A., Al-Batran, S.-E., Arnold, D., 2016.

Ann Oncol 27(6), 149–206, 557P. doi:10.1093/annonc/mdw370.105

Indikation: Kolorektalkarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

AIO KRK 0207
2016

Quality of Life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: A preplanned analysis of the phase III AIO KRK 0207 trial.

Quidde, J., Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C.A., Killing, B., Depenbusch, R., Steffens, C.-C., Lange, T., Dietrich, G., Stoehlmacher, J., Reinacher, A., Tannapfel, A., Trarbach, T., Marschner, N., Schmoll, H.-J., Hinke, A., Al-Batran, S.-E., Arnold, D., 2016.

Ann Oncol 27, 2203–2210. doi:10.1093/annonc/mdw425

Indikation: Kolorektalkarzinom; Veranstaltung: -; Journal: Annals of Oncology

AIO KRK 0207
2016

Systemic palliative treatment in patients with metastatic colorectal cancer tested for their (K)RAS mutation status – Real-life data from the clinical Tumour Registry Colorectal Cancer (TKK).

Zahn, M.-O., Schnell, R., Karcher, A., Schnitzler, M., Wetzel, N., Fleitz, A., Marschner, N., 2016.

Oncol Res Treat 39(suppl5)(V171), 42. ddoi:10.1159/000449050

Indikation: Kolorektalkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TKK
2016

Relevance of neo- or adjuvant pretreatment in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab as first-line treatment – data from the prospective TKK registry.

Schnell, R., Trarbach, T., Broszeit-Luft, S., Musch, R., Wetzel, N., Kopfmann, S., Jänicke, M., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V395), 114. doi:10.1159/000439070

Indikation: Kolorektalkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TKK
2015

Implementation of RAS testing in patients with metastatic colorectal cancer in German outpatient cancer centers – data from the clinical TKK registry.

Schnell, R., Trarbach, T., Broszeit-Luft, S., Musch, R., Frank, M., Kopfmann, S., Jänicke, M., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V394), 113–114. doi:10.1159/000439070

Indikation: Kolorektalkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TKK
2015

Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study.

Marschner, N., Arnold, D., Engel, E., Hutzschenreuter, U., Rauh, J., Freier, W., Hartmann, H., Frank, M., Jänicke, M., 2015.

Clinical Epidemiology 7, 295–303. doi:10.2147/CLEP.S73857

Indikation: Kolorektalkarzinom; Veranstaltung: -; Journal: Journal of Clinical Epidemiology

TKK
2015

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C.A., Killing, B., Depenbusch, R., Steffens, C.-C., Al-Batran, S.-E., Lange, T., Dietrich, G., Stoehlmacher, J., Tannapfel, A., Reinacher-Schick, A., Quidde, J., Trarbach, T., Hinke, A., Schmoll, H.-J., Arnold, D., 2015.

Lancet Oncol. 16, 1355–1369. doi:10.1016/S1470-2045(15)00042-X

Indikation: Kolorektalkarzinom; Veranstaltung: -; Journal: The Lancet

AIO KRK 0207
2015

A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.

Kasper, S., Moehler, M., Hegewisch-Becker, S., Overkamp, F., Bechstein, W.O., Kullmann, F., Lang, H., Schoen, M., Smith-Machnow, V., Seehofer, D., Voehringer, M., Geissler, M., Greil, R., Heike, M., Heinemann, V., Lordick, F., Galle, P.R., Schimanski, C.C., 2014.

J Clin Oncol 32:5s(suppl; abstr TPS3658). doi: 10.1200/jco.2014.32.15_suppl.tps3658

Indikation: Kolorektalkarzinom; Veranstaltung: GI (ASCO); Journal: Journal of Clinical Oncology

LICC
2014

A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and skin prophylaxis aiming to prevent a skin rash.

Goehler, T., Woerns, M.A., Hebart, H.F., Heike, M., Neise, M., Rudi, J., Geer, T., Dingeldein, G., Lang, C., Ehscheidt, P., Flohr, T., Josten, K.M., Karthaus, M., Schmittel, A.H., Wierecky, J., Galle, P.R., Dhensaw, C., Moehler, M.H., Schimanski, C.C., 2014.

J Clin Oncol 32 (suppl; abstr e20724). doi: 10.1200/jco.2014.32.15_suppl.e20724

Indikation: Kolorektalkarzinom; Veranstaltung: ASCO; Journal: Journal of Clinical Oncology

DERMATUX
2014

Effectiveness of bevacizumab beyond progression in patients with metastatic colorectal cancer – data from the clinical TKK registry.

Schnell, R., Musch, R., Broszeit-Luft, S., Harde, J., Kopfmann, S., Jänicke, M., Marschner, N., 2014.

Oncol Res Treat 37(Suppl.5)(V332), 101. doi:10.1159/000368945

Indikation: Kolorektalkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TKK
2014

Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of RP, Oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): Results of the AIO KRK 0207 phase III study.

Hegewisch-Becker, S., Arnold, D., Lerchenmüller, C., Killing, B., Depenbusch, R., Steffens, C.-C., Al-Bartan, S.-E., Lange, T., Dietrich, G., Stoehlmacher, J., Reinacher-Schick, A., Tannapfel, A., Quidde, J., Hinke, A., Schmoll, H.-J., Graeven, U., 2014.

Oncol Res Treat 37 (Suppl.5)(V327), 99 doi:10.1159/000368945

Indikation: Kolorektalkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

AIO KRK 0207
2014

A prognostic score based on tumour characteristics to predict survival of patients with metastatic colorectal cancer: Results from a prospective study.

Marschner, N., Karcher, A., Ladda, E., Franzem, M., Jänicke, M., 2013.

ECCO (2256).

Indikation: Kolorektalkarzinom; Veranstaltung: ECCO (ESMO); Journal: -

TKK
2013

A prognostic score based on tumour characteristics to predict survival of patients with metastatic colorectal cancer: Results from a prospective study.

Marschner, N., Karcher, A., Ladda, E., Franzem, M., Jänicke, M., 2013.Marschner, N., Karcher, A., Ladda, E., Franzem, M., Jänicke, M., 2013.

Onkologie 36 (suppl 7)(V391), 106. doi:10.1159/000356365

Indikation: Kolorektalkarzinom; Veranstaltung: DGHO; Journal: Onkologie

TKK
2013

A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.

Kasper, S., Overkamp, F., Moehler, M., Kullmann, F., Lang, H., Schoen, M., Smith-Machnow, V., Hegewisch-Becker, S., Seehofer, D., Bechstein, W., Heike, M., Voehringer, M., Heinemann, V., Greil, R., Geissler, M., Lordick, F., Peeters, M., Van Cutsem, E., Galle, P.R., Schimanski, C.C., 2013.

J Clin Oncol 31(suppl; abstr TPS3124). doi: 10.1200/jco.2013.31.15_suppl.tps3124

Indikation: Kolorektalkarzinom; Veranstaltung: ASCO; Journal: Journal of Clinical Oncology

LICC
2013

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases–a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.

Schimanski, C.C., Mohler, M., Schon, M., van Cutsem, E., Greil, R., Bechstein, W.O., Hegewisch-Becker, S., von Wichert, G., Vohringer, M., Heike, M., Heinemann, V., Peeters, M., Kanzler, S., Kasper, S., Overkamp, F., Samonigg, H., Seehofer, D., Kullmann, F., Schmidtmann, I., Smith-Machnow, V., Gockel, I., Lang, H., Galle, P.R., 2012.

BMC Cancer 12, 144. doi:10.1186/1471-2407-12-144

Indikation: Kolorektalkarzinom; Veranstaltung: -; Journal: BMC Cancer

LICC
2012

A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of L-BLP25 in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.

Schimanski, C.C., Moehler, M.H., Lang, H., Schoen, M., Smith-Machnow, V., Kanzler, S., Hegewisch-Becker, S., Doerfel, S., Seehofer, D., Bechstein, W., Heike, M., Overkamp, F., Kullmann, F., Voehringer, M., Heinemann, V., von Wichert, G., Kasper, S., Greil, R., Samonigg, H., Galle, P.R., 2012.

J Clin Oncol 30 (suppl 15; Abstract 99605). doi: 10.1200/jco.2012.30.15_suppl.tps3641

Indikation: Kolorektalkarzinom; Veranstaltung: ASCO; Journal: Journal of Clinical Oncology

LICC
2012

Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab?

Hartmann, H., Müller, J., Marschner, N., 2012.

J Clin Oncol 30, 3317–3318. doi:10.1200/JCO.2012.43.3409

Indikation: Kolorektalkarzinom; Veranstaltung: -; Journal: Journal of Clinical Oncology

Indikationsübergreifend
2012

Treatment of younger and elderly colorectal cancer patients in German outpatient centres – data from the clinical TKK registry.

Freier, W., Groschek, M., Schröder, J., von Verschuer, U., Jänicke, M., Marschner, N., 2012.

Onkologie 35 (suppl 6)(P193), 56. doi:10.1159/000170919

Indikation: Kolorektalkarzinom; Veranstaltung: DGHO; Journal: Onkologie

TKK
2012

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases – A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial.

Schimanski, C.C., Galle, P., Lang, H., Schoen, M., Moehler, M., 2011.

J Clin Oncol 29 (suppl)(Abstract TPS166).

Indikation: Kolorektalkarzinom; Veranstaltung: ASCO; Journal: Journal of Clinical Oncology

LICC
2011

A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment.

Mross, K., Büchert, M., Fasol, U., Jaehde, U., Kanefendt, F., Strumberg, D., Arends, J., Hense, J., Moritz, B., Fischer, R., Scheulen, M.E., 2011.

Int J Clin Pharmacol Ther 49, 96–98.

Indikation: Kolorektalkarzinom; Veranstaltung: -; Journal: International Journal of Clinical Pharmacology and Therapeutics

CESAR-C-II-005
2011

Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients.

Kanefendt, F., Lindauer, A., Kinzig, M., Strumberg, D., Scheulen, M.E., Mross, K., Fischer, R., Moritz, B., Sörgel, F., Jaehde, U., 2011.

Int J Clin Pharmacol Ther 49, 88–90.

Indikation: Kolorektalkarzinom; Veranstaltung: -; Journal: International Journal of Clinical Pharmacology and Therapeutics

CESAR-C-II-005
2011

Survival and palliative treatment course of colorectal cancer patients in German outpatient centres. Data from the clinical registry – TKK Registry.

Freier, W., Rauh, J., Kindler, M., Jänicke, M., Marschner, N., 2011.

Onkologie 34 (suppl 6)(V643), 189. doi:10.1159/000333303

Indikation: Kolorektalkarzinom; Veranstaltung: DGHO; Journal: Onkologie

TKK
2011

The pattern of metastases in colorectal cancer. Data from a clinical registry.

Freier, W., Rauh, J., Hutzschenreuter, U., Tessen, H.W., Hartmann, H., Marschner, N., 2010.

Onkologie 33 (suppl 6)(P587), 175. doi:10.1159/000321410

Indikation: Kolorektalkarzinom; Veranstaltung: DGHO; Journal: Onkologie

TKK
2010

The treatment of colorectal cancer in German outpatient centres. Data from a clinical registry. A joint project of the AIO and the AKS.

Freier, W., Schröder, J., Rauh, J., Harich, H.-D., Hartmann, H., 2009.

Onkologie 32 (suppl 4)(P197), 47. doi:10.1159/000242462


Indikation: Kolorektalkarzinom; Veranstaltung: DGHO; Journal: Onkologie

TKK
2009

Colon Registry: Influence of comorbidity on the choice of chemotherapeutic treatment. A joint project of the AIO and the AKS.

Freier, W., Arnold, D., Otremba, B., Marschner, N., 2008.

Onkologie 31 (suppl 4)(P301), 109. doi:10.1159/000161574


Indikation: Kolorektalkarzinom; Veranstaltung: DGHO; Journal: Onkologie

TKK
2008

Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.

Twelves, C.J., 2006.

Clin Colorectal Cancer 6, 278–287.

Indikation: Kolorektalkarzinom; Veranstaltung: -; Journal: Clinical Colorectal Cancer

X-ACT
2006

Capecitabine as adjuvant treatment for stage III colon cancer.

Twelves, C., Wong, A., Nowacki, M.P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., Husseini, F., Jodrell, D., Koralewski, P., Kröning, H., Maroun, J., Marschner, N., McKendrick, J., Pawlicki, M., Rosso, R., Schüller, J., Seitz, J.-F., Stabuc, B., Tujakowski, J., Van Hazel, G., Zaluski, J., Scheithauer, W., 2005.

N Engl J Med 352, 2696–704. doi:10.1056/NEJMoa043116

Indikation: Kolorektalkarzinom; Veranstaltung: -; Journal: New England Journal of Medicine

X-ACT
2005

Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.

Karthaus, M., Ballo, H., Abenhardt, W., Steinmetz, T., Geer, T., Schimke, J., Braumann, D., Behrens, R., Behringer, D., Kindler, M., Messmann, H., Boeck, H.-P., Greinwald, R., Kleeberg, U., 2005.

Oncology 68, 326–32. doi:10.1159/000086971

Indikation: Kolorektalkarzinom; Veranstaltung: -; Journal: Oncology

BUC-37/CID
2005

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

Scheithauer, W., McKendrick, J., Begbie, S., Borner, M., Burns, W.I., Burris, H.A., Cassidy, J., Jodrell, D., Koralewski, P., Levine, E.L., Marschner, N., Maroun, J., Garcia-Alfonso, P., Tujakowski, J., Van Hazel, G., Wong, A., Zaluski, J., Twelves, C., 2003.

Ann. Oncol. 14, 1735–1743.

Indikation: Kolorektalkarzinom; Veranstaltung: -; Journal: Annals of Oncology

X-ACT
2003

Budesonide for prevention of irinotecan (CPT-11)-induced diarrhea. Results of a double-blind, placebo-controlled, multicenter, randomized phase-III-study in patients with advanced colorectal cancer (CRC).

Karthaus, M., Ballo, H., Steinmetz, T., Geer, T., Schimke, J., Braumann, D., Behrens, R., Kindler, M., Greinwald, R., Kleeberg, U., 2003.

Indikation: Kolorektalkarzinom; Veranstaltung: ASCO; Journal: -

BUC-37/CID
2003

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com